ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global GLP-1 Agonist Injection Market Research Report 2025
Published Date: 2025-12-19
|
Report Code: QYRE-Auto-37H16906
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global GLP 1 Agonist Injection Market Research Report 2024
BUY CHAPTERS

Global GLP-1 Agonist Injection Market Research Report 2025

Code: QYRE-Auto-37H16906
Report
2025-12-19
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Amylin
Huadong Medicine
Shanghai Benemae Pharmaceutical Corporation
Novo Nordisk
Sanofi
GSK
Astrazeneca plc
Eli Lilly

GLP-1 Agonist Injection Market

The global market for GLP-1 Agonist Injection was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity. GLP-1 agonist medicines include injections and oral medications.
North American market for GLP-1 Agonist Injection is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for GLP-1 Agonist Injection is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of GLP-1 Agonist Injection include Novo Nordisk, Eli Lilly, AstraZeneca, GSK, Sanofi, Amylin, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for GLP-1 Agonist Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Agonist Injection.
The GLP-1 Agonist Injection market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global GLP-1 Agonist Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GLP-1 Agonist Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of GLP-1 Agonist Injection Market Report

Report Metric Details
Report Name GLP-1 Agonist Injection Market
Segment by Type
  • Short-acting Preparations
  • Long-acting Preparations
Segment by Application
  • Diabetes
  • Obesity
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novo Nordisk, Eli Lilly, AstraZeneca, GSK, Sanofi, Amylin, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of GLP-1 Agonist Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of GLP-1 Agonist Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the GLP-1 Agonist Injection Market report?

Ans: The main players in the GLP-1 Agonist Injection Market are Novo Nordisk, Eli Lilly, AstraZeneca, GSK, Sanofi, Amylin, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation

What are the Application segmentation covered in the GLP-1 Agonist Injection Market report?

Ans: The Applications covered in the GLP-1 Agonist Injection Market report are Diabetes, Obesity

What are the Type segmentation covered in the GLP-1 Agonist Injection Market report?

Ans: The Types covered in the GLP-1 Agonist Injection Market report are Short-acting Preparations, Long-acting Preparations

1 GLP-1 Agonist Injection Market Overview
1.1 Product Definition
1.2 GLP-1 Agonist Injection by Type
1.2.1 Global GLP-1 Agonist Injection Market Value Comparison by Type (2024 VS 2031)
1.2.2 Short-acting Preparations
1.2.3 Long-acting Preparations
1.3 GLP-1 Agonist Injection by Application
1.3.1 Global GLP-1 Agonist Injection Market Value by Application (2024 VS 2031)
1.3.2 Diabetes
1.3.3 Obesity
1.4 Global GLP-1 Agonist Injection Market Size Estimates and Forecasts
1.4.1 Global GLP-1 Agonist Injection Revenue 2020-2031
1.4.2 Global GLP-1 Agonist Injection Sales 2020-2031
1.4.3 Global GLP-1 Agonist Injection Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 GLP-1 Agonist Injection Market Competition by Manufacturers
2.1 Global GLP-1 Agonist Injection Sales Market Share by Manufacturers (2020-2025)
2.2 Global GLP-1 Agonist Injection Revenue Market Share by Manufacturers (2020-2025)
2.3 Global GLP-1 Agonist Injection Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of GLP-1 Agonist Injection, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of GLP-1 Agonist Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of GLP-1 Agonist Injection, Product Type & Application
2.7 Global Key Manufacturers of GLP-1 Agonist Injection, Date of Enter into This Industry
2.8 Global GLP-1 Agonist Injection Market Competitive Situation and Trends
2.8.1 Global GLP-1 Agonist Injection Market Concentration Rate
2.8.2 The Global 5 and 10 Largest GLP-1 Agonist Injection Players Market Share by Revenue
2.8.3 Global GLP-1 Agonist Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global GLP-1 Agonist Injection Market Scenario by Region
3.1 Global GLP-1 Agonist Injection Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global GLP-1 Agonist Injection Sales by Region: 2020-2031
3.2.1 Global GLP-1 Agonist Injection Sales by Region: 2020-2025
3.2.2 Global GLP-1 Agonist Injection Sales by Region: 2026-2031
3.3 Global GLP-1 Agonist Injection Revenue by Region: 2020-2031
3.3.1 Global GLP-1 Agonist Injection Revenue by Region: 2020-2025
3.3.2 Global GLP-1 Agonist Injection Revenue by Region: 2026-2031
3.4 North America GLP-1 Agonist Injection Market Facts & Figures by Country
3.4.1 North America GLP-1 Agonist Injection Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America GLP-1 Agonist Injection Sales by Country (2020-2031)
3.4.3 North America GLP-1 Agonist Injection Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe GLP-1 Agonist Injection Market Facts & Figures by Country
3.5.1 Europe GLP-1 Agonist Injection Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe GLP-1 Agonist Injection Sales by Country (2020-2031)
3.5.3 Europe GLP-1 Agonist Injection Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific GLP-1 Agonist Injection Market Facts & Figures by Region
3.6.1 Asia Pacific GLP-1 Agonist Injection Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific GLP-1 Agonist Injection Sales by Region (2020-2031)
3.6.3 Asia Pacific GLP-1 Agonist Injection Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America GLP-1 Agonist Injection Market Facts & Figures by Country
3.7.1 Latin America GLP-1 Agonist Injection Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America GLP-1 Agonist Injection Sales by Country (2020-2031)
3.7.3 Latin America GLP-1 Agonist Injection Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa GLP-1 Agonist Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa GLP-1 Agonist Injection Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa GLP-1 Agonist Injection Sales by Country (2020-2031)
3.8.3 Middle East and Africa GLP-1 Agonist Injection Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global GLP-1 Agonist Injection Sales by Type (2020-2031)
4.1.1 Global GLP-1 Agonist Injection Sales by Type (2020-2025)
4.1.2 Global GLP-1 Agonist Injection Sales by Type (2026-2031)
4.1.3 Global GLP-1 Agonist Injection Sales Market Share by Type (2020-2031)
4.2 Global GLP-1 Agonist Injection Revenue by Type (2020-2031)
4.2.1 Global GLP-1 Agonist Injection Revenue by Type (2020-2025)
4.2.2 Global GLP-1 Agonist Injection Revenue by Type (2026-2031)
4.2.3 Global GLP-1 Agonist Injection Revenue Market Share by Type (2020-2031)
4.3 Global GLP-1 Agonist Injection Price by Type (2020-2031)
5 Segment by Application
5.1 Global GLP-1 Agonist Injection Sales by Application (2020-2031)
5.1.1 Global GLP-1 Agonist Injection Sales by Application (2020-2025)
5.1.2 Global GLP-1 Agonist Injection Sales by Application (2026-2031)
5.1.3 Global GLP-1 Agonist Injection Sales Market Share by Application (2020-2031)
5.2 Global GLP-1 Agonist Injection Revenue by Application (2020-2031)
5.2.1 Global GLP-1 Agonist Injection Revenue by Application (2020-2025)
5.2.2 Global GLP-1 Agonist Injection Revenue by Application (2026-2031)
5.2.3 Global GLP-1 Agonist Injection Revenue Market Share by Application (2020-2031)
5.3 Global GLP-1 Agonist Injection Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novo Nordisk GLP-1 Agonist Injection Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Company Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Eli Lilly GLP-1 Agonist Injection Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Company Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2020-2025)
6.3.4 AstraZeneca GLP-1 Agonist Injection Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 GSK
6.4.1 GSK Company Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2020-2025)
6.4.4 GSK GLP-1 Agonist Injection Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Company Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sanofi GLP-1 Agonist Injection Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Amylin
6.6.1 Amylin Company Information
6.6.2 Amylin Description and Business Overview
6.6.3 Amylin GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Amylin GLP-1 Agonist Injection Product Portfolio
6.6.5 Amylin Recent Developments/Updates
6.7 Huadong Medicine
6.7.1 Huadong Medicine Company Information
6.7.2 Huadong Medicine Description and Business Overview
6.7.3 Huadong Medicine GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Huadong Medicine GLP-1 Agonist Injection Product Portfolio
6.7.5 Huadong Medicine Recent Developments/Updates
6.8 Shanghai Benemae Pharmaceutical Corporation
6.8.1 Shanghai Benemae Pharmaceutical Corporation Company Information
6.8.2 Shanghai Benemae Pharmaceutical Corporation Description and Business Overview
6.8.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonist Injection Product Portfolio
6.8.5 Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 GLP-1 Agonist Injection Industry Chain Analysis
7.2 GLP-1 Agonist Injection Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 GLP-1 Agonist Injection Production Mode & Process Analysis
7.4 GLP-1 Agonist Injection Sales and Marketing
7.4.1 GLP-1 Agonist Injection Sales Channels
7.4.2 GLP-1 Agonist Injection Distributors
7.5 GLP-1 Agonist Injection Customer Analysis
8 GLP-1 Agonist Injection Market Dynamics
8.1 GLP-1 Agonist Injection Industry Trends
8.2 GLP-1 Agonist Injection Market Drivers
8.3 GLP-1 Agonist Injection Market Challenges
8.4 GLP-1 Agonist Injection Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Amylin
Huadong Medicine
Shanghai Benemae Pharmaceutical Corporation
Novo Nordisk
Sanofi
GSK
Astrazeneca plc
Eli Lilly
List of Tables
 Table 1. Global GLP-1 Agonist Injection Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global GLP-1 Agonist Injection Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global GLP-1 Agonist Injection Market Competitive Situation by Manufacturers in 2024
 Table 4. Global GLP-1 Agonist Injection Sales (K Dose) of Key Manufacturers (2020-2025)
 Table 5. Global GLP-1 Agonist Injection Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global GLP-1 Agonist Injection Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global GLP-1 Agonist Injection Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market GLP-1 Agonist Injection Average Price (US$/Dose) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of GLP-1 Agonist Injection, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of GLP-1 Agonist Injection, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of GLP-1 Agonist Injection, Product Type & Application
 Table 12. Global Key Manufacturers of GLP-1 Agonist Injection, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global GLP-1 Agonist Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GLP-1 Agonist Injection as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global GLP-1 Agonist Injection Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global GLP-1 Agonist Injection Sales by Region (2020-2025) & (K Dose)
 Table 18. Global GLP-1 Agonist Injection Sales Market Share by Region (2020-2025)
 Table 19. Global GLP-1 Agonist Injection Sales by Region (2026-2031) & (K Dose)
 Table 20. Global GLP-1 Agonist Injection Sales Market Share by Region (2026-2031)
 Table 21. Global GLP-1 Agonist Injection Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global GLP-1 Agonist Injection Revenue Market Share by Region (2020-2025)
 Table 23. Global GLP-1 Agonist Injection Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global GLP-1 Agonist Injection Revenue Market Share by Region (2026-2031)
 Table 25. North America GLP-1 Agonist Injection Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America GLP-1 Agonist Injection Sales by Country (2020-2025) & (K Dose)
 Table 27. North America GLP-1 Agonist Injection Sales by Country (2026-2031) & (K Dose)
 Table 28. North America GLP-1 Agonist Injection Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America GLP-1 Agonist Injection Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe GLP-1 Agonist Injection Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe GLP-1 Agonist Injection Sales by Country (2020-2025) & (K Dose)
 Table 32. Europe GLP-1 Agonist Injection Sales by Country (2026-2031) & (K Dose)
 Table 33. Europe GLP-1 Agonist Injection Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe GLP-1 Agonist Injection Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific GLP-1 Agonist Injection Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific GLP-1 Agonist Injection Sales by Region (2020-2025) & (K Dose)
 Table 37. Asia Pacific GLP-1 Agonist Injection Sales by Region (2026-2031) & (K Dose)
 Table 38. Asia Pacific GLP-1 Agonist Injection Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific GLP-1 Agonist Injection Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America GLP-1 Agonist Injection Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America GLP-1 Agonist Injection Sales by Country (2020-2025) & (K Dose)
 Table 42. Latin America GLP-1 Agonist Injection Sales by Country (2026-2031) & (K Dose)
 Table 43. Latin America GLP-1 Agonist Injection Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America GLP-1 Agonist Injection Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa GLP-1 Agonist Injection Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa GLP-1 Agonist Injection Sales by Country (2020-2025) & (K Dose)
 Table 47. Middle East and Africa GLP-1 Agonist Injection Sales by Country (2026-2031) & (K Dose)
 Table 48. Middle East and Africa GLP-1 Agonist Injection Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa GLP-1 Agonist Injection Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global GLP-1 Agonist Injection Sales (K Dose) by Type (2020-2025)
 Table 51. Global GLP-1 Agonist Injection Sales (K Dose) by Type (2026-2031)
 Table 52. Global GLP-1 Agonist Injection Sales Market Share by Type (2020-2025)
 Table 53. Global GLP-1 Agonist Injection Sales Market Share by Type (2026-2031)
 Table 54. Global GLP-1 Agonist Injection Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global GLP-1 Agonist Injection Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global GLP-1 Agonist Injection Revenue Market Share by Type (2020-2025)
 Table 57. Global GLP-1 Agonist Injection Revenue Market Share by Type (2026-2031)
 Table 58. Global GLP-1 Agonist Injection Price (US$/Dose) by Type (2020-2025)
 Table 59. Global GLP-1 Agonist Injection Price (US$/Dose) by Type (2026-2031)
 Table 60. Global GLP-1 Agonist Injection Sales (K Dose) by Application (2020-2025)
 Table 61. Global GLP-1 Agonist Injection Sales (K Dose) by Application (2026-2031)
 Table 62. Global GLP-1 Agonist Injection Sales Market Share by Application (2020-2025)
 Table 63. Global GLP-1 Agonist Injection Sales Market Share by Application (2026-2031)
 Table 64. Global GLP-1 Agonist Injection Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global GLP-1 Agonist Injection Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global GLP-1 Agonist Injection Revenue Market Share by Application (2020-2025)
 Table 67. Global GLP-1 Agonist Injection Revenue Market Share by Application (2026-2031)
 Table 68. Global GLP-1 Agonist Injection Price (US$/Dose) by Application (2020-2025)
 Table 69. Global GLP-1 Agonist Injection Price (US$/Dose) by Application (2026-2031)
 Table 70. Novo Nordisk Company Information
 Table 71. Novo Nordisk Description and Business Overview
 Table 72. Novo Nordisk GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 73. Novo Nordisk GLP-1 Agonist Injection Product
 Table 74. Novo Nordisk Recent Developments/Updates
 Table 75. Eli Lilly Company Information
 Table 76. Eli Lilly Description and Business Overview
 Table 77. Eli Lilly GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 78. Eli Lilly GLP-1 Agonist Injection Product
 Table 79. Eli Lilly Recent Developments/Updates
 Table 80. AstraZeneca Company Information
 Table 81. AstraZeneca Description and Business Overview
 Table 82. AstraZeneca GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 83. AstraZeneca GLP-1 Agonist Injection Product
 Table 84. AstraZeneca Recent Developments/Updates
 Table 85. GSK Company Information
 Table 86. GSK Description and Business Overview
 Table 87. GSK GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 88. GSK GLP-1 Agonist Injection Product
 Table 89. GSK Recent Developments/Updates
 Table 90. Sanofi Company Information
 Table 91. Sanofi Description and Business Overview
 Table 92. Sanofi GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 93. Sanofi GLP-1 Agonist Injection Product
 Table 94. Sanofi Recent Developments/Updates
 Table 95. Amylin Company Information
 Table 96. Amylin Description and Business Overview
 Table 97. Amylin GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 98. Amylin GLP-1 Agonist Injection Product
 Table 99. Amylin Recent Developments/Updates
 Table 100. Huadong Medicine Company Information
 Table 101. Huadong Medicine Description and Business Overview
 Table 102. Huadong Medicine GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 103. Huadong Medicine GLP-1 Agonist Injection Product
 Table 104. Huadong Medicine Recent Developments/Updates
 Table 105. Shanghai Benemae Pharmaceutical Corporation Company Information
 Table 106. Shanghai Benemae Pharmaceutical Corporation Description and Business Overview
 Table 107. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 108. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonist Injection Product
 Table 109. Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. GLP-1 Agonist Injection Distributors List
 Table 113. GLP-1 Agonist Injection Customers List
 Table 114. GLP-1 Agonist Injection Market Trends
 Table 115. GLP-1 Agonist Injection Market Drivers
 Table 116. GLP-1 Agonist Injection Market Challenges
 Table 117. GLP-1 Agonist Injection Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of GLP-1 Agonist Injection
 Figure 2. Global GLP-1 Agonist Injection Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global GLP-1 Agonist Injection Market Share by Type: 2024 & 2031
 Figure 4. Short-acting Preparations Product Picture
 Figure 5. Long-acting Preparations Product Picture
 Figure 6. Global GLP-1 Agonist Injection Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global GLP-1 Agonist Injection Market Share by Application: 2024 & 2031
 Figure 8. Diabetes
 Figure 9. Obesity
 Figure 10. Global GLP-1 Agonist Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global GLP-1 Agonist Injection Market Size (2020-2031) & (US$ Million)
 Figure 12. Global GLP-1 Agonist Injection Sales (2020-2031) & (K Dose)
 Figure 13. Global GLP-1 Agonist Injection Average Price (US$/Dose) & (2020-2031)
 Figure 14. GLP-1 Agonist Injection Report Years Considered
 Figure 15. GLP-1 Agonist Injection Sales Share by Manufacturers in 2024
 Figure 16. Global GLP-1 Agonist Injection Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest GLP-1 Agonist Injection Players: Market Share by Revenue in GLP-1 Agonist Injection in 2024
 Figure 18. GLP-1 Agonist Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global GLP-1 Agonist Injection Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America GLP-1 Agonist Injection Sales Market Share by Country (2020-2031)
 Figure 21. North America GLP-1 Agonist Injection Revenue Market Share by Country (2020-2031)
 Figure 22. United States GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe GLP-1 Agonist Injection Sales Market Share by Country (2020-2031)
 Figure 25. Europe GLP-1 Agonist Injection Revenue Market Share by Country (2020-2031)
 Figure 26. Germany GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific GLP-1 Agonist Injection Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific GLP-1 Agonist Injection Revenue Market Share by Region (2020-2031)
 Figure 33. China GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. China Taiwan GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Latin America GLP-1 Agonist Injection Sales Market Share by Country (2020-2031)
 Figure 41. Latin America GLP-1 Agonist Injection Revenue Market Share by Country (2020-2031)
 Figure 42. Mexico GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Brazil GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Argentina GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Colombia GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Middle East and Africa GLP-1 Agonist Injection Sales Market Share by Country (2020-2031)
 Figure 47. Middle East and Africa GLP-1 Agonist Injection Revenue Market Share by Country (2020-2031)
 Figure 48. Turkey GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. UAE GLP-1 Agonist Injection Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Global Sales Market Share of GLP-1 Agonist Injection by Type (2020-2031)
 Figure 52. Global Revenue Market Share of GLP-1 Agonist Injection by Type (2020-2031)
 Figure 53. Global GLP-1 Agonist Injection Price (US$/Dose) by Type (2020-2031)
 Figure 54. Global Sales Market Share of GLP-1 Agonist Injection by Application (2020-2031)
 Figure 55. Global Revenue Market Share of GLP-1 Agonist Injection by Application (2020-2031)
 Figure 56. Global GLP-1 Agonist Injection Price (US$/Dose) by Application (2020-2031)
 Figure 57. GLP-1 Agonist Injection Value Chain
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Global Oral GLP 1 Agonist Market Research Report 2024
Global GLP 1 Agonists for Obesity Market Research Report 2024
Global Glucagon Like Peptide 1 GLP 1 Agonists Market Research Report 2025
Global Antidiabetic Glucagon like Peptide 1 Agonists Market Research Report 2025
Global Glucagon like peptide 1 GLP 1 based Therapies Market Research Report 2025
Global GLP 1 Receptor Agonist Drugs Market Research Report 2024
GLP Analogs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024
Global GLP 1 Injection Market Research Report 2024
Global GLP 1 Drug Peptide API Market Research Report 2024
Global GLP 1 Receptor Antagonist Market Research Report 2024
GLP 1 Analogues Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1 Weight Loss Injection Market Research Report 2024
GLP 1 for Weight Loss Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1 Drugs Market Research Report 2024
Global GLP 1 Injection Pen Market Research Report 2024
Global GLP 1 based Therapy Market Research Report 2024
Global GLP 1 Weight Loss Drug Market Research Report 2024
Global GLP 1RA Therapy Market Research Report 2024
Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions